Xiulong (Mark) Shen

Xiulong (Mark) Shen has a diverse work experience in the field of biology and research. Xiulong (Mark) started their career as an Undergraduate Research Assistant at Tianjin University in 2009 before moving on to become a Graduate Teaching and Research Assistant at the University of Missouri-Columbia. During their time at the University, Xiulong designed, synthesized, and characterized benzotriazine mono-N-oxides analogs for the detection of drug-related bioreductive enzymes.

After completing their graduate studies, Xiulong joined UT Southwestern Medical Center as a Postdoctoral Researcher in 2017. Xiulong (Mark) worked in Dr. David R. Corey lab, focusing on studying the mechanism of RNA-mediated control of gene expression. Their research centered on exploring methods to upregulate expression of frataxin in Friedreich's Ataxia patient-derived cell models and defining the protein partners involved in nuclear RNA interference.

Since 2020, Xiulong has been associated with Entrada Therapeutics. Xiulong (Mark) began their journey as a Scientist I in Discovery Biology and later progressed to become a Scientist II. Currently, Xiulong holds the position of Senior Scientist, where they are responsible for identifying and validating novel disease targets for oligonucleotides-peptide conjugates. Xiulong (Mark) also designs and optimizes oligonucleotide sequences for DNA and RNA targets.

Xiulong (Mark) Shen pursued their education starting in 2007 at Tianjin University, where they completed their Bachelor of Science (B.S.) in Pharmaceutical Science and Technology in 2011. Xiulong (Mark) went on to continue their studies at the University of Missouri-Columbia from 2011 to 2016, where they earned their Doctor of Philosophy (Ph.D.) in Chemistry.